Bing Yao, ArriVent Biopharma CEO

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Ar­riVent Bio­phar­ma will join the Nas­daq on Fri­day morn­ing in a strong start to biotech’s first batch of ini­tial pub­lic of­fer­ings this year.

The Penn­syl­va­nia drug­mak­er said Thurs­day night it would sell 9.72 mil­lion shares $AVBP at $18 apiece, the mid­point of the range it pro­posed ear­li­er this week. The late-stage biotech will raise $175 mil­lion in its up­sized of­fer­ing.

The list­ing comes a day af­ter the first biotech IPO of the year, in which Phase III blad­der can­cer drug­mak­er CG On­col­o­gy drew in $380 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA